21-hydroxy Oligomycin A
(Synonyms: 21羟基寡霉素A) 目录号 : GC15881An anticancer antibiotic
Cas No.:102042-09-1
Sample solution is provided at 25 µL, 10mM.
21-hydroxy Oligomycin A is an antibiotic which was first isolated from S. cyaneogriseus ssp.noncyanogenus [1]. 21-hydroxy Oligomycin A functions as μM inhibitor of the multidrug efflux pump P-gp, and low nM inhibitors of K-Ras PM localization [1].
Cancer cell viability screening confirmed that 21-hydroxy Oligomycin A was cytotoxic to human colorectal carcinoma cells (IC50 > 3 μM), and was inhibitor of the ABC transporter efflux pump P-glyco-protein (P-gp). Significantly, 21-hydroxy Oligomycin A was exceptionally potent inhibitor of K-Ras PM localisation with Emax of 0.67–0.75 and an IC50 of 1.5–14 nM [1]. 21-hydroxy Oligomycin A was inhibitor of K-Ras PM localisation in MDCK cell with an IC50 of 4.82 ± 0.70 nM. 21-hydroxy Oligomycin A was moderately cytotoxic towards both SW620 and SW620 Ad300 cells with the IC50 of 14.4 ± 0.6 and 11.8 ± 3.1 μM, respectively. In the flow cytometry assay, 21-hydroxy Oligomycin A (20 μM) increased intracellular calcein fluorescence significantly when compared with the negative control [1].
Reference:
[1] Salim A A, Tan L, Huang X C, et al. Oligomycins as inhibitors of K-Ras plasma membrane localisation[J]. Organic & biomolecular chemistry, 2016, 14(2): 711-715.
Cas No. | 102042-09-1 | SDF | |
别名 | 21羟基寡霉素A | ||
化学名 | (1R,2'S,4E,5'S,6S,6'S,7R,8S,10R,11R,12S,14R,15S,16R,18E,20E,22R,25S,28S,29R)-22-ethyl-3',4',5',6'-tetrahydro-7,11,14,15,23-pentahydroxy-6'-[(2R)-2-hydroxypropyl]-5',6,8,10,12,14,16,28,29-nonamethyl-spiro[2,26-dioxabicyclo[23.3.1]nonacosa-4,18,20-triene-27 | ||
Canonical SMILES | O=C([C@@H](C)[C@H](O)[C@@H](C)/C=C/1)[C@H](C)[C@@H](O)[C@H](C)C([C@@](O)(C)[C@@H](O)[C@H](C)C/C=C/C=C/[C@H](CC)[C@H](O)C[C@@]2([H])[C@@H](C)[C@@]([C@H](C)[C@@]3(CC[C@H](C)[C@@](C[C@H](O)C)([H])O3)O2)([H])OC1=O)=O | ||
分子式 | C45H74O12 | 分子量 | 807.1 |
溶解度 | DMF: Soluble,DMSO: Soluble,Ethanol: Soluble,Methanol: Soluble | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.239 mL | 6.195 mL | 12.39 mL |
5 mM | 0.2478 mL | 1.239 mL | 2.478 mL |
10 mM | 0.1239 mL | 0.6195 mL | 1.239 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet